174 related articles for article (PubMed ID: 9649245)
1. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors.
Pode D; Golijanin D; Sherman Y; Lebensart P; Shapiro A
J Urol; 1998 Feb; 159(2):389-92; discussion 393. PubMed ID: 9649245
[TBL] [Abstract][Full Text] [Related]
2. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
Golijanin D; Sherman Y; Shapiro A; Pode D
Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
[TBL] [Abstract][Full Text] [Related]
3. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.
Golijanin D; Shapiro A; Pode D
J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of bladder cancer with urinary cytology, immunocytology and DNA-image-cytometry.
Planz B; Synek C; Deix T; Böcking A; Marberger M
Anal Cell Pathol; 2001; 22(3):103-9. PubMed ID: 11455029
[TBL] [Abstract][Full Text] [Related]
5. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder.
Planz B; Striepecke E; Jakse G; Böcking A
J Urol; 1998 Feb; 159(2):384-7; discussion 387-8. PubMed ID: 9649244
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
[TBL] [Abstract][Full Text] [Related]
7. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
8. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
10. [Role of immunocytology in the evaluation of patients with painless gross hematuria].
Schmitz-Dräger BJ; Tirsar LA; Schmitz-Dräger C; Dörsam J; Ebert T; Bismarck E
Urologe A; 2010 Jun; 49(6):741-6. PubMed ID: 20373094
[TBL] [Abstract][Full Text] [Related]
11. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity.
Kavaler E; Landman J; Chang Y; Droller MJ; Liu BC
Cancer; 1998 Feb; 82(4):708-14. PubMed ID: 9477104
[TBL] [Abstract][Full Text] [Related]
12. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
14. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
Sawczuk IS; Pickens CL; Vasa UR; Ralph DA; Norris KA; Miller MC; Ng AY; Grossman HB; Veltri RW
Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
18. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
19. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
[TBL] [Abstract][Full Text] [Related]
20. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
